[211At]At-girentuximab

N/A

Report date: 2025/12/05 20:00:50
NME

Base Information

Drug Name[211At]At-girentuximab
Drug Alias Name211At-girentuximab[211At]At-anti-CA-IX AntibodyATO-101
ClassificationRadiation-emitting products > Nuclides > Astatine > 211AtRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates
Mechanisms of ActionAnti-Carbonic anhydrase IX
TargetsCarbonic anhydrase IX
Therapy Area/IndicationsUrinary Bladder Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesATONCOInstitut de Cancérologie de l'Ouest
China Registration ClassN/A

Develop Information

Active CompaniesInstitut de Cancérologie de l'OuestInstitut De Cancerologie De L OuestATONCO
Inactive CompaniesN/A
Active IndicationsUrinary Bladder Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A